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ABSTRACT. This overview describes recent advances in molecular biology of neuronal ceroid lipofuscinoses (CLN). Despite intensive research during last 20 years, the basic defects of these autosomal recessive-progressive encephalopathies of childhood remain unknown. Consequently, no specific cure is available. Methods of positional cloning (reverse genetics) starting from random linkage approach have been applied to search for gene defects in the infantile and juvenile forms of the disease. The results of this random search for disease loci have for the first time revealed molecular heterogeneity of CLN diseases. The gene defect causing the infantile form has been assigned to lp32 in the Finnish family material, whereas the disease locus of the juvenile form has been localized to 16p12 in European and Canadian families. Finally, the gene defect causing the late infantile form has been excluded from both lp32 and 16p12 chromosomal regions, referring to a third, still unknown locus causing CLN disease. Consequently, reliable prenatal and carrier diagnostics have now become possible in families with the infantile and juvenile forms of the disease, and DNA-based prenatal diagnostics have been successfully applied in the infantile form. Most importantly, the assignment of gene loci has brought these fatal brain diseases within the reach of molecular cloning strategies that eventually will result in revealing both the infantile and juvenile CLN genes and in identifying corresponding gene products. (Pediatr Res 32: 645-648, 1992) Abbreviations CLN, ceroid lipofuscinosis, neuronal CLN1, infantile neuronal ceroid lipofuscinosis CLN2, late infantile neuronal ceroid lipofuscinosis CLN3, juvenile neuronal ceroid lipofuscinosis MRI, magnetic resonance imaging stance common to the different forms of CLN resembles lipopigment, showing autofluorescence and acid phosphatase activity and intense staining with the Sudan black B and periodic acid Schiff methods. These properties are similar to those of lipofuscin and ceroid. Lipofuscin is a compound known to accumulate in most cell types with age. It is caused by nonspecific peroxidation of polyunsaturated fatty acids present in complex lipids of different membranes. Ceroid is also a compound with some characteristics of lipofuscin, but it is formed mainly in certain experimental and pathologic conditions (4) . These morphologic findings are highly nonspecific in nature, and, consequently, numerous theories (5-8) are put forward to explain the pathology of CLN diseases. However, no fruitful clues to elucidate the metabolic basis of these brain diseases have been suggested. (2, 9) . A fourth type, adult CLN (Kufs' disease, CLN4, McKusick 204300), is typically a rare form in adults and will not be considered further here. The classification of CLN is based on the age of onset, clinical course of the disease, neurologic, ophthalmologic, neurophysiologic, and ultrastructural findings (Table 1) (2). All childhood forms are inherited as an autosomal recessive trait. About 10% of all CLN patients represent variant or atypical forms, which are dificult to classify into the three main childhood groups (10) (11) (12) (13) (14) . Repeated clinical examinations of the patients and sufficient follow-up times provide diagnostic accuracy in uncertain cases. These patients usually have features common to both the late infantile and juvenile forms and are classified as the late infantile group, which, consequently, can actually represent several disease entities.
CLN is one of the most common progressive encephalopathies AND in Western countries (1, 2) . The main features of this disease are CLNI, The infantile form is the earliest and most severe form failure of ps~chomotor development, impaired vision, seizures, of^^^. ~h~ first symptoms appear at 8 to 20 mo ofage, and in familial occurrence, and premature death. The term neuronal the follow-up the disease is characterized by rapid psychomotor ceroid lipofuscinosis was introduced in 1969 by E m a n and deterioration, muscular hypotonia, microcephaly, ataxia, thoDyken (3) to distinguish these disorders from other types of reoathetosis, myoclonic jerks, and knitting hyperkinesia. Partial amaurotic family idiocy. Despite intensive research during the and generalized seizures and, occasionally, Lennox-like synlast 20 years, the enzyme defects of this group of neurometabolic drome are seen. Anxiety and hyperexcitability are apparent in diseases still remain unknown. The accumulated storage sub-most Datients at the age of to 2.5 v. Visual svmDtoms, slow MRI intensity changes appear early, even before clinical signs classic CLN2, this perhaps represents a phenomenon secondary (1 6). The ultrastructural picture of the tissue usually performed to the primary gene defect (8) . as a suction biopsy from the rectum shows granular osmiophilic
In computed tomography and MRI, brain atrophy correlates deposits (17) . The mean age of death is about 10 y.
with age and is pronounced early in CLNl (22, 23) . With CLN 1 is enriched in the population of Finland, the incidence repeated clinical examinations and follow-up, the progressive being I in 20 000. A total of 124 CLNl patients have been nature of all CLN diseases is revealed and the diagnosis successdescribed in the genetically isolated Finnish population of 5 fully found (Table 1) . million inhabitants during last 20 y, whereas about 100 cases have been reported from other populations.
ASSIGNMENT OF CLNl AND CLN3
Rett's syndrome is the most important differential diagnostic disease, especially in girls at the age of 1.5-2 because of the The positional cloning strategy was to map the CLN knitting hyperkinesia that is typical in the children suffering from diseases because biochemical or histochemical studies had rethis disorder (1 8). Early autism, acute cerebellar ataxia, enceph-vealed genes No alitis, epilepsies, and prenatal disorders are also imponant for it^ has been reported in these patients that could have served as differential diagnostics. a starting point for mapping the gene defect.
CLN2. The first symptoms of the classic late infantile form
Recent in mapping the human genome with start after 2 of age with epilepsy and dementia and also with ~o l~~o~~~~~ have created to map any gene retarded speech development. Ataxia and myoclonia occur soon causing a human disease-even rare recessive phenotypesafterwards. Typically, visual failure appears after the neurologic provided relevant family material is available (24) . symptoms. Neurophysiologic studies have proved to be especially Using linkage of the random assigned to important in this form because of typical spikes induced by low individual chromosomes, the locus for CLN3 (Batten's disease) photic in EEG and high-amplitude Curve found in was ~uccessfully assigned to the short arm of chromosome 16 the visual-evoked potential test. The ultrastructural investigation (25) (26) (27) in 58 European and Canadian families. Soon thereafter, of different tissues of these patients reveal curvilinear profiles of the gene causing CLN1 was mapped to chromosome 1p32 in 40 unknown origin. Death occurs between 6 and 15 y of age. Finnish nuclear families (28) (Fig. 1) . When markers demonstratIncidence estimates are hard to find, although this form is ing linkage to CLN3 and CLNl were analyzed in 26 classic relatively common in Great and North America (2, 1 9 ) CLN2 families, definitive exclusion of this locus from these Most of the atypical or forms of CLN resemble the chromosomal regions was established. This finding refers to a classic CLN2. One of them is the cluster of 16 families with the third still-unidentified locus in the human genome for CLN variant CLN2 in Finland (20, ) . Another similar group has diseases, which would be responsible for CLN2 (2 1, Williams R, been found in Great Britain (10) and a third in Newfoundland Vesa J, McKay T, Mitchison H, Jarvela I, Thompson A, Callen (14) . The clinical picture and neurophysiologic findings of these D, Sutherland G, Luna-Battadano D, Stallings R, Peltonen L, forms resemble the classic CLN2, but the ultrastructural inves-Gardiner RM, unpublished observations). Currently, CLNl is tigation reveals fingerprint profiles, storage of the unknown assigned to a chromosomal region covering about 5 centimorgans between the markers D 1 S57 and D l S62 at lp32. CLN3 has been material accumulated in different tissues, in some cases resem-assigned to an approximate 2-centimorgan region between the bling the juvenile form (20) . MRI intensity changes appear early markers 6S67 and 6S 148 (27) . These distances are still in the Finnish variant cases (22) . The age at onset, as well as the considerable at the molecular level, corresponding to about age at death, is somewhat later than in the classic form (2) . million (CLNI) and 2 million (CLN3) bp of the DNA strands, CLN3. The juvenile form, or Batten's disease, is the most respectively. However, the disease loci are now well defined in type CLN in the with the highest incidence the human genome, with border-lining markers facilitating the in North European countries. The first clinical symptom is visual use of molecular cloning strategies, allowing identification of the failure starting at 4-7 Y. After 10 Y of age, mental retardation, corresponding genes. The observed linkage disequilibrium found epilepsy and parkinsonism-like motor clumsiness occur. Typical with some markers in CLN chromosomes versus non-CLN chrodiagnostic signs are retinal pigment aggregations and vacuolated mosomes actually suggests that the distance to the disease gene lymphocytes in peripheral blood. Fingerprint profiles are found is shorter than the one predicted from genetic distance between in ultrastructural investigation. Life expectancy is 13-40 y (2) . the markers (2 ) .
CLN3 is the form of CLN diseases in which a biochemical finding with some specificity has recently been described. specialists and actually formed a solid base for mapping of the disease loci involved. False phenocopies and locus heterogeneity in small family materials could have been fatal for the linkage approach. Due to the enrichment of the rare CLNl gene in the isolated Finnish population, the mapping of this gene was possible only in Finland and also supported the hypothesis of one locus behind this form.
Strong linkage disequilibrium has been found with several polymorphic markers in the vicinity of L-MYC at lp32 in CLNI chromosomes of the Finnish patients (21) . With one multiallelic marker, 95% of the affected CLNl chromosomes and 87% of the diseased children represent the same homozygote haplotype, whereas all the non-Finnish patients have different allele combinations. This suggests that one mutation causes CLNl in Finland due to founder effect. The situation is highly analogous to the situation reported in the case of a lysosomal accumulation disease, aspartylglucosaminuria, also enriched in this isolated population, as one mutation is found to cause 98% of the cases in Finland opposed to the spectrum of different mutations found in patients from other populations (29) .
PRENATAL AND CARRIER DIAGNOSTICS
Prenatal and carrier diagnostics have been required especially by CLNl families after one affected child was born in the family. In such severe disorders with a high risk of recurrence (25%), reliable prenatal diagnostics can help the families planning additional pregnancies. Fifteen pregnancies at risk for CLN 1 have so far been analyzed in our laboratory using DNA markers linked to CLNI, and the results have been compared with the electron 
